Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9

International Journal of Cancer

Volumn 113, Issue 5, 2005, Pages 803-810

  Ding, Haiming ^a   Han, Chunhua ^a   Zhu, Jiuxiang ^b   Chen, Ching Shih ^b,c   D'Ambrosio, Steven M ^a,c,d,e  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e Division of Radiobiology   (United States)

Author keywords

Akt; Apoptosis; Caspase; Celecoxib; Chemoprevention; Erk1 2; Mitochondrial; Oral cancer

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ASPARTYLGLUTAMINYLVALYLASPARTIC ACID; CASPASE 3; CASPASE 8; CASPASE 9; CELECOXIB; CYCLOOXYGENASE 2; CYCLOSPORIN A; ENZYME INHIBITOR; ISOLEUCYLGLUTAMINYLTHREONYLASPARTIC ACID; LEUCYLGLUTAMINYLHISTIDYLASPARTIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BCL 2; PROTEIN KINASE B; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROTEIN DEGRADATION;

APOPTOSIS; CARDIOVASCULAR DISEASES; CASPASE 9; CASPASES; CELL DIVISION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; ENZYME ACTIVATION; G2 PHASE; HUMANS; ISOENZYMES; MEMBRANE POTENTIALS; MEMBRANE PROTEINS; MITOCHONDRIA; MOUTH NEOPLASMS; PHOSPHORYLATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZOLES; SULFONAMIDES;

EID: 11944270441     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20639     Document Type: Article

References (49)

1. Reddy BS, Rao CV. Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. J Environ Pathol Toxicol Oncol 2002;21:155-64.
2. Sudbo J, Reith A. Which putatively pre-malignant oral lesions become oral cancers? J Oral Pathol Med 2003;32:63-70.
3. Sudbo J, Ristimaki A, Sondresen JE, Kildal W, Boysen M, Koppang HS, Reith A, Risberg B, Nesland JM, Bryne M. Cyclooxygenase-2 (COX-2) expression in high-risk premalignant oral lesions. Oral Oncol 2003;39:497-505.
4. Ding H, Han C, Gibson-D'Ambrosio R, Steele VE, D'Ambrosio SM. Piroxicam selectively inhibits the growth of premalignant and malignant human oral cell lines by limiting their progression through the S phase and reducing the levels of cyclins and AP-1. Int J Cancer 2003;107:830-6.
5. Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBois RN. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 2000;60:6045-51.
6. Denkert C, Furstenberg A, Daniel PT, Koch I, Kobel M, Weichert W, Siegert A, Hauptmann S. Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. Oncogene 2003;22:8653-61.
7. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 2002;62:2029-33.
8. Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, Chen CS. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. JNCI 2002;94:1745-57.
9. Jiang XH, Lam SK, Lin MC, Jiang SH, Kung HF, Slosberg ED, Soh JW, Weinstein IB, Wong BC. Novel target for induction of apoptosis by cyclo-oxygenase-2 inhibitor SC-236 through a protein kinase C-beta(1)-dependent pathway. Oncogene 2002;21:6113-22.
10. Wick M, Hurteau G, Dessev C, Chan D, Geraci MW, Winn RA, Heasley LE, Nemenoff RA. Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol 2002;62:1207-14.
11. Hwang DH, Fung V, Dannenberg AJ. National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanisms. Neoplasia 2002;4:91-7.
12. Vainio H. Is COX-2 inhibition a panacea for cancer prevention? Int J Cancer 2001;94:613-4.
13. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001;15:2057-72.
14. Raz A. Is inhibition of cyclooxygenase required for the anti-tumorigenic effects of nonsteroidal, anti-inflammatory drugs (NSAIDs)? In vitro versus in vivo results and the relevance for the prevention and treatment of cancer. Biochem Pharmacol 2002;63:343-7.
15. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. JNCI 2002;94:252-66.
16. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001;15:2742-4.
17. Baliga BC, Kumar S. Role of Bcl-2 family of proteins in malignancy. Hematol Oncol 2002;20:63-74.
18. Crompton M, Barksby E, Johnson N, Capano M. Mitochondrial intermembrane junctional complexes and their involvement in cell death. Biochimie 2002;84:143-152.
19. Fischer U, Janicke RU, Schulze-Osthoff K. Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ 2003;10:76-100.
20. Kim R, Tanabe K, Uchida Y, Emi M, Inoue H, Toge T. Current status of the molecular mechanisms of anticancer drug-induced apoptosis: the contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother Pharmacol 2002;50:343-52.
21. Kiechle FL, Zhang X. Apoptosis: biochemical aspects and clinical implications. Clin Chim Acta 2002;326:27-45.
22. Chen M. Wang J. Initiator caspases in apoptosis signaling pathways. Apoptosis 2002;7:313-9.
23. Parone PA, James D, Martinou JC. Mitochondria: regulating the inevitable. Biochimie 2002;84:105-11.
24. Chandra D, Tang DG. Mitochondrially localized active caspase-9 and caspase-3 result mostly from translocation from the cytosol and partly from caspase-mediated activation in the organelle. Lack of evidence for Apaf-1-mediated procaspase-9 activation in the mitochondria. J Biol Chem 2003;278:17408-20.
25. Kim JS, He L, Lemasters JJ. Mitochondrial permeability transition: a common pathway to necrosis and apoptosis. Biochem Biophys Res Commun 2003;304:463-70.
26. Jendrossek V, Handrick R, Belka C. Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB Journal 2003;17:1547-9.
27. Krause MM, Brand MD, Krauss S, Meisel C, Vergin H, Burmester GR, Buttgereit F. Nonsteroidal antiinflammatory drugs and a selective cyclooxygenase 2 inhibitor uncouple mitochondria in intact cells. Arthritis Rheum 2003;48:1438-44.
28. Totzke G, Schulze-Osthoff K, Janicke RU. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition. Oncogene 2003;22:8021-30.
29. Yang CC, Lin HP, Chen CS, Yang YT, Tseng PH, Rangnekar VM, Chen CS. Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells. J Biol Chem 2003;278:25872-8.
30. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The Cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000;275:11397-403.
31. Song X, Lin HP, Johnson AJ, Tseng PH, Yang YT, Kulp SK, Chen CS. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. JNCI 2002;94:585-91.
32. Zhu J, Huang J-W, Fowble JW, Tseng PH, Yang YT, Shiau C-W, Shaw Y-J, Kulp SK, Chen CS. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 2004;64:4309-18.
33. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, Fowble JW, Ward PJ, Chen CS. 3-Phosphoinositide-Dependent Protein Kinase-1/Akt Signaling Represents a Major Cyclooxygenase-2-Independent Target for Celecoxib in Prostate Cancer Cells. Cancer Res 2004;64:1444-51.
34. Milo GE, Shuler C, Kurian P, French BT, Mannix DG, Noyes I, Hollering J, Sital N, Schuller DE, Trewyn RW. Nontumorigenic squamous cell carcinoma line converted to tumorigenicity with methyl methanesulfonate without activation of HRAS or MYC. Proc Natl Acad Sci U S A 1990;87:1268-72.
35. Johnson AJ, Song X, Hsu A, Chen CS. Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells. Adv Enzyme Regul 2001;41:221-235.
36. Beauparlant P, Shore GC. Therapeutic activation of caspases in cancer: a question of selectivity. Curr Opin Drug Discov Devel 2003;6:179-87.
37. Robertson JD, Orrenius S. Role of mitochondria in toxic cell death. Toxicology 2002;181:491-6.
38. Herendeen JM, Lindley C. Use of NSAIDs for the chemoprevention of colorectal cancer. Ann Pharmacother 2003;37:1664-74.
39. Gumgumji AA, Dawood T, Parvez T. Role of COX-2 specific inhibitors in oncogenesis. J Coll Physicians Surg Pak 2003;13:361-5.
40. Scheid MP, Woodgett JR. Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett 2003;546:108-12.
41. Fujita N, Sato S, Katayama K, Tsuruo T. Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J Biol Chem 2002;277:28706-13.
42. Zhou BP, Hung MC. Novel targets of Akt, p21(Cip1/WAF1), and MDM2. Semin Oncol 2002;29:62-70.
43. Roberts EC, Shapiro PS, Nahreini TS, Pages G, Pouyssegur J, Ahn NG. Distinct cell cycle timing requirements for extracellular signal-regulated kinase and phosphoinositide 3-kinase signaling pathways in somatic cell mitosis. Mol Cell Biol 2002;22:7226-41.
44. Jirmanova L, Afanassieff M, Gobert-Gosse S, Markossian S, Savatier P. Differential contributions of ERK and PI3-kinase to the regulation of cyclin D1 exypression and to the control of the G1/S transition in mouse embryonic stem cells. Oncogene 2002;21:5515-28.
45. Toker A. Phosphoinositides and signal transduction. Cell Mol Life Sci 2002;59:761-779.
46. Lorenzo HK, Susin SA. Mitochondrial effectors in caspase-independent cell death. FEBS Letters 2004;557:14-20.
47. Kroemer G. Mitochondrial control of apoptosis: an introduction. Biochem Biophys Res Commun 2003;304:433-5.
48. Engels IH, Stepczynska A, Stroh C, Lauber K, Berg C, Schwenzer R, Wajant H, Janicke RU, Porter AG, Belka C, Gregor M, Schulze-Osthoff K, Wesselborg S. Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. Oncogene 2000;19:4563-73.
49. von Haefen C, Wieder T, Essmann F, Schulze-Osthoff K, Dorken B, Daniel PT. Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop. Oncogene 2003;22:2236-47.